genedrive plc (GDR) - Total Liabilities

Latest as of June 2025: GBX1.38 Million GBX ≈ $167.54 USD

Based on the latest financial reports, genedrive plc (GDR) has total liabilities worth GBX1.38 Million GBX (≈ $167.54 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

genedrive plc - Total Liabilities Trend (2006–2025)

This chart illustrates how genedrive plc's total liabilities have evolved over time, based on quarterly financial data. See GDR current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

genedrive plc Competitors by Total Liabilities

The table below lists competitors of genedrive plc ranked by their total liabilities.

Company Country Total Liabilities
LMS Capital Plc
LSE:LMS
UK GBX1.22 Million
I.Ceram SA
PA:ALICR
France €3.48 Million
RTC Group plc
LSE:RTC
UK GBX13.33 Million
CleanTech Lithium plc
LSE:CTL
UK GBX18.39 Million
LEPU MED.T.B. SP.GDR O.N.
F:07Z0
Germany €7.61 Billion
Xeros Technology Group Plc
LSE:XSG
UK GBX1.11 Million
Galileo Resources Plc
LSE:GLR
UK GBX303.15K
Meyer Burger Tech AG
SW:MBTN
Switzerland CHF545.59 Million

Liability Composition Analysis (2006–2025)

This chart breaks down genedrive plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see genedrive plc stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.95 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.96 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.49 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how genedrive plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for genedrive plc (2006–2025)

The table below shows the annual total liabilities of genedrive plc from 2006 to 2025.

Year Total Liabilities Change
2025-06-30 GBX1.38 Million
≈ $167.54
-4.44%
2024-06-30 GBX1.44 Million
≈ $175.33
-41.57%
2023-06-30 GBX2.47 Million
≈ $300.04
+144.16%
2022-06-30 GBX1.01 Million
≈ $122.89
-21.40%
2021-06-30 GBX1.28 Million
≈ $156.35
-90.69%
2020-06-30 GBX13.79 Million
≈ $1.68K
+41.71%
2019-06-30 GBX9.73 Million
≈ $1.18K
+16.66%
2018-06-30 GBX8.35 Million
≈ $1.02K
-3.02%
2017-06-30 GBX8.61 Million
≈ $1.05K
+6.20%
2016-06-30 GBX8.10 Million
≈ $985.90
+25.67%
2015-06-30 GBX6.45 Million
≈ $784.54
+71.86%
2014-06-30 GBX3.75 Million
≈ $456.51
+86.02%
2013-06-30 GBX2.02 Million
≈ $245.41
+25.67%
2012-06-30 GBX1.60 Million
≈ $195.28
-1.35%
2011-06-30 GBX1.63 Million
≈ $197.96
-19.73%
2010-06-30 GBX2.03 Million
≈ $246.63
-35.77%
2009-06-30 GBX3.16 Million
≈ $383.99
+444.14%
2008-06-30 GBX580.00K
≈ $70.57
-21.83%
2007-06-30 GBX742.00K
≈ $90.28
+88.32%
2006-06-30 GBX394.00K
≈ $47.94
--

About genedrive plc

LSE:GDR UK Diagnostics & Research
Market Cap
$153.46K
GBX1.26 Billion GBX
Market Cap Rank
#31180 Global
#1057 in UK
Share Price
GBX1.23
Change (1 day)
+0.00%
52-Week Range
GBX0.23 - GBX1.50
All Time High
GBX217.89
About

genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnos… Read more